FM
REGN icon

Freemont Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Freemont Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,600
Closed -$5.09M – 148
2025
Q4 		$5.09M Buy
+6,600
New +$4.48M 0.89% 30

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Freemont Management's REGN Position: Q1 2026 in Review

Freemont Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 6,600 shares — an estimated $5.09M sold.

Freemont Management first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $5.09M in Q4 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Freemont Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Freemont Management sold 6,600 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $5.09M.
  • Freemont Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Freemont Management's Regeneron Pharmaceuticals position peaked at $5.09M in Q4 2025.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Freemont Management's 13F filing for Q1 2026, filed 6 May 2026.